The safety profile at 7.2 mg was broadly consistent with what is already known about semaglutide
Log each BPC-157 injection (time, dose, site)
In response to the UK regulator's warning, 'Novo Nordisk', the manufacturer of Wegovy and Ozempic, stated, "We recommend that patients only use these medications for their approved indications and under the strict supervision of a healthcare professional." 'Eli Lilly', the manufacturer of Mounjaro, said, "The Mounjaro patient information leaflet specifies that acute pancreatitis is an uncommon side effect that may affect up to 1 in 100 people." The MHRA plans to conduct a separate study on patients using GLP-1 class drugs
Meanwhile, Asia Pacific is expected to witness significant growth during the forecast period, driven by rising healthcare expenditures, increasing disease prevalence, improving healthcare access, and expanding awareness regarding advanced therapeutic options